NDA 020808 · Ge Healthcare
Visipaque 270
Iodixanol · Injection · Radiographic Contrast Agent
Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Aug 29, 1997
Approved uses
2
Original approval plus efficacy supplements
Registered trials
50
6 Phase 3, 0 recruiting
FAERS reports
3,613
3,321 serious, 273 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NOT FOR INTRATHECAL USE Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema. ( 4 , 5.1 )
What it is approved for
From the label in effect Oct 16, 2026.
VISIPAQUE is indicated for: VISIPAQUE injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 and 320 mg Iodine/mL). Excretory urography (270 and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 and 320 mg Iodine/mL) CT imaging of the head and body. (270 and 320 mg Iodine/mL) excretory urography....
Mechanism: Intravascular injection of iodixanol opacifies vessels in the path of flow of the contrast agent, permitting visualization of internal structures. In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In a normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the interstitial space in the region of disruption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 5, 2017 Supplement 25 · Efficacy · priority review LabelLetterReview
- Aug 29, 1997 Original approval · Type 3 - New Dosage Form
2 products under this application
- VISIPAQUE 270 · IODIXANOL 55% · INJECTABLE, INJECTION · Discontinued
- VISIPAQUE 320 · IODIXANOL 65.2% · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Iodixanol" as an intervention, any sponsor and status, largest first.
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed TomographyPivotal-lookingTerminated
GE HealthcareIndustry
NCT00209417 · 656 participants · Start Jun 2005 · Primary completion May 2011
Drug: Iodixanol 320-Arm 1; Iopamidol 300-Arm 2 · For: Renal Insufficiency; Diabetes Mellitus
Sites: Princeton, New Jersey; Amersham, United Kingdom
- A Safety Comparison of Iopromide and Iodixanol in Renal Impaired PatientsPivotal-lookingCompleted
Chinese PLA General HospitalAcademic, hospital or other
NCT00926562 · 592 participants · Start Feb 2009 · Primary completion Dec 2010
Drug: Iopromide (Ultravist); Iodixanol (Visipaque) · For: Kidney Failure, Chronic
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 19 sites in all
- Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)Pivotal-lookingCompleted
Ospedale San DonatoAcademic, hospital or other
NCT00827788 · 432 participants (planned) · Start Dec 2008 · Primary completion Apr 2010
Drug: Iodixanol; Iopromide · For: Contrast Induced Nephropathy; Acute Myocardial Infarction
Sites: Arezzo, Italy
- Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus IopromidePivotal-lookingCompleted
Seoul National University Bundang HospitalAcademic, hospital or other
NCT00823628 · 420 participants (planned) · Start Feb 2009 · Primary completion May 2010
Drug: contrast agent (iopromide); contrast agent (iodixanol) · For: Chronic Renal Insufficiency; Coronary Angiography
Sites: Seongnam-si, South Korea
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary AngiographyPivotal-lookingCompleted
GE HealthcareIndustry
NCT00209430 · 408 participants · Start Aug 2005
Drug: Iodixanol 320 mgI/mL · For: Coronary Artery Disease; Renal Impairment
Sites: Solna, Sweden
- Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CINPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT02718521 · 400 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Visipaque; 0.9% sodium chloride fluid administration and 1 more · For: Cardio-Renal Syndrome
Sites: Beijing, China
- A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac AngiographyPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT00289029 · 400 participants · Start Jul 2005
Drug: Iopamidol 370 mgI/mL · For: CIN
Sites: Princeton, New Jersey
- Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00390585 · 324 participants · Start Jul 2006 · Primary completion Jan 2008
Drug: Iodixanol 320; Iomeprol 350 · For: Renal Insufficiency, Chronic; Angioplasty, Transluminal, Percutaneous Coronary; Coronary Arteriosclerosis
Sites: Munich, Germany; München, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus478
- rash306
- erythema275
- dyspnoea257
- urticaria233
- nausea180
- hypotension158
- vomiting157
- acute kidney injury143
- contrast media allergy136
- anaphylactic reaction128
- rash maculo-papular120
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 49 |
| 2005 | 42 |
| 2006 | 69 |
| 2007 | 57 |
| 2008 | 73 |
| 2009 | 56 |
| 2010 | 82 |
| 2011 | 136 |
| 2012 | 135 |
| 2013 | 191 |
| 2014 | 282 |
| 2015 | 197 |
| 2016 | 220 |
| 2017 | 200 |
| 2018 | 169 |
| 2019 | 236 |
| 2020 | 170 |
| 2021 | 136 |
| 2022 | 106 |
| 2023 | 201 |
| 2024 | 239 |
| 2025 | 283 |
| 2026 | 284 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials.
Han XF, Zhang XX, Liu KM, et al. · PLoS One 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy.
Chicaíza-Becerra LA, García-Molina M, Gamboa Ó · Biomedica 2012 · Comparative Study, Research Support, Non-U.S. Gov't
- [Optimal x-ray contrast media for ambulatory coronary angiography from the microcirculatory point of view].
Bach R, Jung F · Herz 1998 · Clinical Trial, Randomized Controlled Trial
- A systematic review of cost-effectiveness analyses across the acute kidney injury landscape.
Suh K, Kellum JA, Kane-Gill SL · Expert Rev Pharmacoecon Outcomes Res 2021 · Comparative Study, Systematic Review
- Refining the assessment of contrast-induced acute kidney injury: the load-to-damage relationship.
Limbruno U, Picchi A, Micheli A, et al. · J Cardiovasc Med (Hagerstown) 2014 · Comparative Study, Randomized Controlled Trial
- Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis.
Suh YJ, Yoon SH, Hong H, et al. · Invest Radiol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Ge Healthcare · Also marketed as Visipaque 320
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.